CoChat
Sign Up
Cited by 380Immune Cell Function and InteractionAcute Myeloid Leukemia ResearchImmune cells in cancer

Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction

Fauriat, Cyril, Just-Landi, Sylvaine, Mallet, Françoise, Arnoulet, Christine, Sainty, Danielle, Olive, Daniel, Costello, Regis T.·2007·Blood
DOI 10.1182/blood-2005-08-027979
Open this paper in CoChat — free account

Abstract

Natural killer (NK) cells play an important role in tumor-cell clearance, particularly against leukemia, as shown by killer cell inhibitory receptor (KIR)–mismatched allogeneic stem cell transplantation. Analysis of in vitro IL-2–expanded NK cells from patients with myelocytic/monocytic acute myeloid leukemia (AML-NK cells) has revealed poor cytolytic functions because of deficient expression of pivotal activation molecules—the natural cytotoxicity receptors (NCRs) NKp30, NKp44, and NKp46. To exclude the possibility that this observation was caused by the in vitro amplification of a small NCRdull population, we analyzed the AML-NK phenotype directly, without any in vitro expansion. We first confirmed that the NCRdull phenotype was not an in vitro artifact. Moreover, analysis of a large population of AML patients allowed us to demonstrate that phenotype was not restricted to a French-American-British (FAB) subtype and was not associated with a particular cytogenetic abnormality. Our longitudinal study of AML patients showed that the NCRdull phenotype was acquired during leukemia development because we observed its complete (for NKp46) or partial (for NKp30) reversibility in patients achieving complete remission (CR). Reversibility of the NCRdull phenotype after CR suggested that leukemia cells might be involved in NCR down-regulation. In agreement with this hypothesis, direct contact between leukemic blasts and NK cells (but not leukemia-cell supernatants) induced loss or decrease in NKp30 and NKp46 expression while impeding NKp44 induction by IL-2. We excluded the major implication of TGF-β in NCR down-regulation. Although the clinical antitumor value of NK cells is clearly demonstrated in allogeneic stem cell transplantation, the role of NK cells in autologous transplantation is not proved. Interestingly, we observed a correlation between the NCRdull phenotype and poor survival in AML patients, suggesting that NK-deficient activation caused by NCR down-regulation could play a role in patient outcome. The prognostic value of NCR expression is discussed, and pathophysiologic implication of the NCR phenotype will be further investigated in a larger study.

Integrity signals

Registry

Crossref · 10.1182/blood-2005-08-027979

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • NKp30, NKp46, and DNAM-1 are NK activation receptors involved in the recognition and lysis of different tumors, such as hematological malignancies, melanoma, and ovarian cancer.

    “Moreover, NKp30, NKp46, and DNAM-1 are NK activation receptors involved in the recognition and lysis of different tumors, such as hematological malignancies [82], melanoma [83], and ovarian cancer [84].”

    From Immunosenescence: a key player in cancer development (2020) · cites this paper as [82]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Fauriat, C., Just-Landi, S., Mallet, F., Arnoulet, C., Sainty, D., Olive, D., & Costello, R. T.
Affiliations
  • Inserm (FR)
  • Laboratoire d'Immunologie des Tumeurs, Institut National de la Santé et de la Recherche Médicale (INSERM) Unite Mixté de Recherche (UMR) 599, and
  • Institut Paoli-Calmettes (FR)
  • Aix-Marseille Université (FR)
ORCID
Venue
Blood
Publisher
American Society of Hematology
Published
2006-08-29
Volume
109
Issue
1
Pages
323-330
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2005-08-027979
OpenAlex
W1964982854
Cited by
380
References
30
Citations by year
2026: 4 · 2025: 16 · 2024: 20 · 2023: 24 · 2022: 17 · 2021: 28 · 2020: 29 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 21 · 2015: 21 · 2014: 16 · 2013: 27 · 2012: 18
FWCI
4.04
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fondation pour la Recherche Médicale
  • Ligue Contre le Cancer
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
natural cytotoxicity receptors, natural killer cells, acute myeloid leukemia, NKp30, NKp44, NKp46, leukemia cells, NK cell activation, complete remission, prognostic factors, survival, TGF-beta, interleukin-2, NK cell cytotoxicity, autologous transplantation
MeSH terms
Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Cell Differentiation, Cell Transformation, Neoplastic, Cytotoxicity, Immunologic, Female, Hematopoietic Stem Cells, Humans, Interleukin-2, Killer Cells, Natural, Leukemia, Myeloid, Male, Membrane Glycoproteins, Middle Aged, Neoplasm Proteins, Receptors, Immunologic, Remission Induction, Tumor Cells, Cultured, Neoplastic Stem Cells, Gene Expression Regulation, Leukemic, Survival Analysis, Coculture Techniques, Kaplan-Meier Estimate, Natural Cytotoxicity Triggering Receptor 1, Natural Cytotoxicity Triggering Receptor 3, Natural Cytotoxicity Triggering Receptor 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review